vibostolimab
Selected indexed studies
- The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. (Future Oncol, 2024) [PMID:39230120]
- Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy. (J Immunother Cancer, 2025) [PMID:40829901]
- Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. (Lancet Oncol, 2026) [PMID:41698381]
_Worker-drafted node — pending editorial review._
Connections
vibostolimab is a side effect of
Sources
- The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. (2024) pubmed
- Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy. (2025) pubmed
- Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. (2026) pubmed
- Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G. (2026) pubmed
- First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(☆). (2022) pubmed
- Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. (2025) pubmed
- Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. (2026) pubmed
- Anti-TIGIT therapies for solid tumors: a systematic review. (2023) pubmed
- TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. (2023) pubmed
- Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT. (2023) pubmed